by Truveta Research | Jan 20, 2026 | Research
As of December 2025, GLP-1 RA prescriptions account for more than 7% of all prescriptions. Tirzepatide continues to be the most prescribed anti-diabetic (ADM) and anti-obesity (AOM) medication (sold as Mounjaro and Zepbound, respectively) and showed the largest...
by Truveta staff | Jan 15, 2026 | Research
Type 1 diabetes (T1D) affects far fewer people than type 2, but the stakes for each person are higher. It’s a lifelong, minute-by-minute autoimmune condition. People with T1D depend on insulin to survive, and small improvements in glucose control can translate into...
by Truveta staff | Jan 7, 2026 | Research
For people who experience a first non-cardioembolic ischemic stroke (NCIS) or transient ischemic attack (TIA), the danger doesn’t end at hospital discharge. New research presented at the 2025 World Stroke Congress shows that the risk of recurrent events and...
by Truveta Research | Jan 2, 2026 | Research
Authors: Nina B. Masters, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Brianna M. Goodwin Cartwright, MS ⊕Truveta, Inc, Bellevue, WA, Patricia J. Rodriguez, PhD, MPH ⊕Truveta, Inc, Bellevue, WA, Karen G. Farrar, PhD ⊕Truveta, Inc, Bellevue, WA, Duy Do, PhD ⊕Truveta, Inc,...
by Truveta Research | Dec 11, 2025 | Research
Respiratory virus–associated hospitalizations increased overall in November 2025 (+91.1%) and now make up 2.5% of all hospitalizations. Respiratory virus–associated hospitalizations increased substantially among children aged 0-4 years old (+73.1%), reaching 3.9% of...
by Truveta Research | Dec 9, 2025 | Research, Research Insights
Among women prescribed a semaglutide or tirzepatide medication, the percentage with a PCOS diagnosis increased from 4.6% in 2021 to 5.7% in 2025, a 23.9% relative increase. Nearly all PCOS patients prescribed semaglutide or tirzepatide also had obesity or type 2...
